These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18026728)

  • 1. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
    Takimoto CH; Awada A
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):535-48. PubMed ID: 18026728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
    Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
    Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
    Dal Lago L; D'Hondt V; Awada A
    Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
    Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
    Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
    J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
    Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2007 May; 73(9):1308-17. PubMed ID: 17266941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
    Duran I; Hotté SJ; Hirte H; Chen EX; MacLean M; Turner S; Duan L; Pond GR; Lathia C; Walsh S; Wright JJ; Dancey J; Siu LL
    Clin Cancer Res; 2007 Aug; 13(16):4849-57. PubMed ID: 17699864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
    Clark JW; Eder JP; Ryan D; Lathia C; Lenz HJ
    Clin Cancer Res; 2005 Aug; 11(15):5472-80. PubMed ID: 16061863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    Egberts F; Kahler KC; Livingstone E; Hauschild A
    Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
    Tran MA; Smith CD; Kester M; Robertson GP
    Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
    Robert C; Mateus C; Spatz A; Wechsler J; Escudier B
    J Am Acad Dermatol; 2009 Feb; 60(2):299-305. PubMed ID: 19028406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
    Strumberg D; Awada A; Hirte H; Clark JW; Seeber S; Piccart P; Hofstra E; Voliotis D; Christensen O; Brueckner A; Schwartz B
    Eur J Cancer; 2006 Mar; 42(4):548-56. PubMed ID: 16426838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.